Learn about the health benefits of cruciferous vegetables and vegetables in this short video. Tips for both men and women. In her new book Life Is Your Best Medicine, Dr. Tieraona Low Dog weaves together the wisdom of traditional medicine and the knowledge of modern-day medicine into an elegant message of health and self-affirmation for women of every age. http://bit.ly/LifeMedicine Health and Wellness
According to the results of a recent study conducted by researchers at the USDA-Agricultural Research Service Western Human Nutrition Research Center, the Northwest Cherry Growers are pleased to announce that consuming about 45 (280 g) sweet Bing cherries significantly decreased circulating concentrations of specific inflammatory biomarkers in the blood. According to Dr. Kent Erickson, Professor at UC Davis School of Medicine and a collaborator in the study, “Many studies by other investigators have demonstrated that some of those inflammation markers are associated with increased risk for some chronic diseases such as cardiovascular disease, diabetes, and cancer.” The findings of the study have been published in the March 2013 issue of The Journal of Nutrition.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61851-northwest-cherries-usda-study-health-benefits
OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
Reproductive Medicine Associates of New Jersey (http://www.rmanj.com) today presented interim findings from its BEST (Blastocyst Euploid Selective Transfer) trial, the first well-controlled clinical trial comparing in vitro fertilization (IVF) pregnancy rates in a group of women receiving a single embryo transfer (SET) with comprehensive chromosome screening (CCS) with a group receiving traditional morphology-based double embryo transfer (DET). The findings were presented at the American Society for Reproductive Medicine 68th Annual Meeting in San Diego, October 20-24, 2012.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58883-rmanj-best-trial-results-ivf-pregnancy-rates-women-asrm-annual-meeting
The Preeclampsia Foundation today released the Illustrated Preeclampsia Symptoms Tear Pad, a patient education tool that was developed in collaboration with health services researchers at Northwestern University Feinberg School of Medicine in Chicago, Ill. The tool effectively informs pregnant women, even those with potentially poor literacy, about preeclampsia. Because preeclampsia is a disorder that can have grave consequences for a mother and her unborn baby, the goal is for the tool to offer information in a way that allows women to assimilate and retain knowledge related to preeclampsia, leading them to promptly seek medical attention should they have symptoms related to preeclampsia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61626-preeclampsia-foundation-illustrated-symptoms-tear-pad-for-pregnant-women
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, Epilog.us [http://www.Epilog.us], now features a panel discussion of leading experts on the role of rational polytherapy in the treatment of patients with epilepsy, led by Dr. Barry Gidal, Professor of Pharmacy and Neurology/Division Chair, University of Wisconsin. Dr. Gidal also brings forward discussion on the mechanism of action of specific antiepileptic drugs (AEDs). Additional topics include: AED pharmacokinetics; patient adherence and AEDs; and drug interactions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59891-upsher-smith-epilog-us-pharmacodynamics-of-antiepileptic-drugs-aeds
With the ultimate goal of preventing half a million teens from abusing medicine within five years, The Partnership at Drugfree.org will launch The Medicine Abuse Project during the week of September 23-29, 2012. The launch week will kick start a multi-year effort to help educate parents, teens and the public about the dangers of medicine abuse and unite parents, educators, health care providers, coaches, government officials, law enforcement officers and other partners to help save lives.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54143-the-partnership-at-drugfree-org-medicine-abuse-project-teen-education
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
GetWellNetwork®, the health care technology company that pioneered Interactive Patient Care™, introduced today a model for enhanced patient and family engagement that mirrors the fundamentals of precision medicine. Supported by The Patient’s Platform™ — a cross-continuum suite of integrated solutions, tools and strategies — Precision Engagement™ delivers uniquely personalized care guided by a person’s ability to take an active role in their health journey.
To view the multimedia release go to:
https://www.multivu.com/players/English/8151751-getwellnetwork-precision-engagement-the-patient-platform/
As the cold and flu season peaks, adults may take multiple over-the-counter (OTC) pain medicines to treat their pain and fever symptoms. Yet many are unaware of the serious liver or gastrointestinal damage that can result from the overdose or overuse of common OTC pain medicine ingredients. To help adults safely take these medicines, the American Gastroenterological Association (AGA) today launched Gut Check: Know Your Medicine, an education campaign focused on the safe use of OTC products. Central to the campaign is a unique flipbook-style video that highlights the importance of reading and following OTC medicine labels.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65680-american-gastroenterological-aga-gut-check-know-your-medicine-otc-psa
For the millions who suffer from Gastroesophageal Reflux Disease (GERD), a study published today in the New England Journal of Medicine (NEJM) provides clinical evidence of safety and effectiveness for a new, FDA-approved medical device. Torax Medical’s LINX® Reflux Management System was studied in a controlled, prospective, multicenter trial involving 14 U.S. and European medical centers as part of the FDA pre-market approval process. The patients were evaluated before and after treatment to determine the effect of the LINX System on their GERD using pre-defined success criteria, which included reduction of esophageal acid, improvement in quality of life and elimination of reflux medications.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60077-torax-medical-linx-reflux-management-system-clinical-study-published
